NPPA caps retail prices for 23 new drug formulations in India
India’s drug-pricing regulator has notified maximum retail prices, excluding GST, for 23 new formulations spanning diabetes, cardiac, mental-health, infection and pain therapies. Identical products launched within 12 months must be priced at or below the notified level.
What happened
National Pharmaceutical Pricing Authority (NPPA) · India's NPPA fixed maximum retail prices, excluding GST, for 23 new drug formulations across diabetes,
Key facts
- 23 new drug formulations
- DPCO 2013
- 12 months
- 42 formulations in May 2026
- 30 formulations in June 2026
Why this matters
Corporate-development teams should incorporate NPPA price ceilings and the 12-month comparable-product rule into India licensing, acquisition and launch diligence, particularly for pipeline assets in the covered therapy areas.
What to watch
- NPPA publication of detailed formulation-wise ceiling prices, pack definitions and effective dates.
- Clarifications on what qualifies as an identical product and how the 12-month launch rule will be enforced.
- Additional NPPA price notifications covering high-volume chronic therapies or commonly prescribed fixed-dose combinations.
- Company disclosures of price cuts, inventory provisions, reduced trade schemes or changes to launch guidance.
- Changes in pharmacy dispensing mix, generic substitution rates and availability of capped formulations across urban and rural channels.
- Any industry litigation, representation or request for exemptions related to the notified formulations.
- Audit all affected SKUs and formulations launched or planned within the 12-month comparability window; revise MRPs excluding GST and distributor price lists.
- Recalculate gross-to-net economics by channel, including retailer and stockist margins, scheme spending, returns and inventory revaluation exposure.
- Shift promotional emphasis toward adherence, availability and branded differentiation in diabetes, cardiac and mental-health portfolios where price competition is likely to rise.
- Review launch pipeline for products likely to be deemed identical or comparable, and redesign pack sizes, strengths or value propositions only where clinically and legally defensible.
- Pharmacy chains and e-pharmacies should update catalog pricing, flag affected inventory and use improved affordability to drive substitution, refill retention and chronic-care basket growth.